Pyrotinib is an orally administered, irreversible tyrosine kinase inhibitor (TKI) of the pan-ErbB receptor, which has been authorized for the therapy of HER2-amplified breast cancer in recurrent and neoadjuvant settings (Blair, 2018). This evidence concerns the gene ERBB2 and breast cancer.